Aflibercept versus ranibizumab for cystoid macular oedema secondary to central retinal vein occlusion

被引：0
|
作者：
Karampelas, Michael [1 ]
Waxman, Jacob [1 ]
Barampouti, Foteini Faye [1 ]
机构：
[1] West Herts NHS Trust, Ophthalmol, London, England
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2018年 / 59卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
4286
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A retrospective comparison of aflibercept and ranibizumab in the management of macular oedema secondary to retinal vein occlusion
    Di Simplicio, Sandro
    Hogg, Jeff
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [2] Aflibercept versus bevacizumab and/or ranibizumab for recurrent macular edema secondary to central retinal vein occlusion
    Dedania, Vaidehi
    Ozgonul, Cem
    Besirli, Cagri G.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [3] Aflibercept Versus Bevacizumab and/or Ranibizumab for Recurrent Macular Edema Secondary to Central Retinal Vein Occlusion
    Ozgonul, Cem
    Dedania, Vaidehi S.
    Besirli, Cagri G.
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2018, 34 (04) : 340 - 345
  • [4] Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab
    Vasileios Konidaris
    Zahra Al-Hubeshy
    Konstantinos T. Tsaousis
    Konstantina Gorgoli
    Somnath Banerjee
    Theodoros Empeslidis
    International Ophthalmology, 2018, 38 : 207 - 213
  • [5] Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab
    Konidaris, Vasileios
    Al-Hubeshy, Zahra
    Tsaousis, Konstantinos T.
    Gorgoli, Konstantina
    Banerjee, Somnath
    Empeslidis, Theodoros
    INTERNATIONAL OPHTHALMOLOGY, 2018, 38 (01) : 207 - 213
  • [6] Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab
    T D Papakostas
    L Lim
    T van Zyl
    J B Miller
    B S Modjtahedi
    C M Andreoli
    D Wu
    L H Young
    I K Kim
    D G Vavvas
    D D Esmaili
    D Husain
    D Eliott
    L A Kim
    Eye, 2016, 30 : 79 - 84
  • [7] Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab
    Papakostas, T. D.
    Lim, L.
    van Zyl, T.
    Miller, J. B.
    Modjtahedi, B. S.
    Andreoli, C. M.
    Wu, D.
    Young, L. H.
    Kim, I. K.
    Vavvas, D. G.
    Esmaili, D. D.
    Husain, D.
    Eliott, D.
    Kim, L. A.
    EYE, 2016, 30 (01) : 79 - 84
  • [8] Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion
    Irini Chatziralli
    George Theodossiadis
    Panagiotis Theodossiadis
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255 : 1459 - 1460
  • [9] Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion
    Chatziralli, Irini
    Theodossiadis, George
    Theodossiadis, Panagiotis
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2017, 255 (07) : 1459 - 1460
  • [10] Comment on: 'Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab'
    Calugaru, D.
    Calugaru, M.
    EYE, 2016, 30 (05) : 766 - 766
12345